Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor

Li, Yinghuan; Wang, Jie; Wientjes, M. Guillaume; Au, Jessie L.-S.

doi:10.1016/j.addr.2011.04.006

Cited by 199 publications

(188 citation statements)

References 134 publications

(126 reference statements)

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the design of pH-responsive nanostructures is considered a great approach to facilitate the drug release into the cytosol by destabilizing endosomal membranes under mildly acidic conditions (Chen et al 2009). Agents commonly used to promote NP escape/release from endosomes include pH-sensitive peptides and surfactants, pH-buffering polymers, and fusogenic lipids (Li et al 2012;Nogueira et al 2014b).…”

Section: Ph-dependent Membrane-lytic Activity Of Nanoparticlesmentioning

confidence: 99%

“…The clinical efficacy of the conventional treatments is often compromised by the acquisition of resistance in cancer cells and/or by the generation of several side effects to the patients (Banerjee et al 2002;Dong and Mumper 2010). In this context, the nanotechnology-based pharmaceutical products might provide a wide range of new tools and possibilities in cancer therapy, from earlier diagnostics to more efficient and more targeted treatments (Chen et al 2014;Das and Sahoo 2011;Li et al 2012). …”

Section: Introductionmentioning

confidence: 99%

“…Likewise, there is considerable progress already achieved regarding the mechanisms underlying drug release from the nanostructures, being most of the current release methods based on reactions that commonly occur in response to environmental factors, 4 i.e. the acidic conditions of subcellular compartments (Li et al 2012). Therefore, the knowledge about this mechanism gave basis for the research of pH-responsive nanocarriers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy

et al. 2015

View full text Add to dashboard Cite

The encapsulation of antitumor drugs in nanosized systems with pH-sensitive behavior is a promissing approach that may enhance the success of chemotherapy in many cancers. The nanocarrier dependence on pH might trigger an efficient delivery of the encapsulated drug both in the acidic extracellular environment of tumors and, especially, in the intracellular compartments through disruption of endosomal membrane. In this context, here we reported the preparation of chitosan-based nanoparticles encapsulating methotrexate as a model drug (MTX-CS-NPs), which comprises the incorporation of an amino acid-based amphiphile with pHresponsive properties (77KS) on the ionotropic complexation process. The presence of 77KS clearly gives a pH-sensitive behavior to NPs, which allowed accelerated release of MTX with decreasing pH as well as pH-dependent membrane-lytic activity. This latter performance demonstrates the potential of these NPs to facilitate cytosolic delivery of endocytosed materials.Outstandingly, the cytotoxicity of MTX-loaded CS-NPs was higher than free drug to MCF-7 tumor cells and, to a lesser extent, to HeLa cells. Based on the overall results, MTX-CS-NPs modified with the pH-senstive surfactant 77KS could be potentially useful as a carrier system for intracellular drug delivery and, thus, a promising targeting anticancer chemotherapeutic agent.

show abstract

Section: Ph-dependent Membrane-lytic Activity Of Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…DOX, D/PP@M/GNP or D/ PSP@M@GNP were intravenously injected into the mice at a dose of 10 mg/kg DOX per mouse after the tumor volume reached 500 mm 3 . The tumor size and animal body weight were measured every 2 d during the study, and the volume of tumors was calculated by the following formula: volume (mm 3 ) D 1/2 A (length) £ B (width) 2 After a 24-h administration, the mice were anesthetized with 4% chloral hydrate and sacrificed; the main organs were removed to be observed with an in vivo fluorescence imaging system (CRi Maestro TX, USA). For HPLC-MS/MS analysis (Agilent 1260, USA), tumors or organs were homogenized with 1 mL water, to which 500 mL acetonitrile containing 100 ng/mL daunorubicin (Sigama-Aldrich, D8809) as internal standard was added.…”

Section: In Vitro Penetration Assay Using Tumor Spheroidsmentioning

confidence: 99%

“…First, the physiological barriers of the tumor restrict the effective distribution of the therapeutics to all tumor cells. 1,2 Second, the acquired drug resistance resulting from monotherapy cripples the antitumor efficiency of available drugs. 3,4 Codelivery nanocarriers have shown the potential to overcome these 2 challenges or reduce their effects.…”

Section: Introductionmentioning

confidence: 99%

A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery

et al. 2016

View full text Add to dashboard Cite

To further enhance the intensity of deep tumor drug delivery and integrate a combined therapy, we herein report on a core-shell nanocarrier that could simultaneously overcome the double barriers of the extracellular matrix (ECM) and multiple layers of tumor cells (MLTC). A pH-triggered reversible swelling-shrinking core and an MMP2 (matrix metallopeptidase 2) degradable shell were developed to encapsulate chemotherapeutics and macroautophagy/autophagy inhibitors, respectively. MMP2 degraded the shell, which was followed by the autophagy inhibitors' release. The exposed core could diffuse along the pore within the ECM to deliver chemotherapeutics into deep tumors, and it was able to swell in lysosomes and shrink back in the cytoplasm or ECM. The swelling of the core resulted in the rapid release of chemotherapeutics to kill autophagy-inhibited cells. After leaving the dead cells, the shrinking core could act on neighboring cells that were closer to the center of the tumor. The core thus could also cross MLTC layer by layer to deliver chemotherapeutics into the deep tumor.

show abstract

Virus‐Inspired Mimics Based on Dendritic Lipopeptides for Efficient Tumor‐Specific Infection and Systemic Drug Delivery

Zhang

et al. 2015

Adv Funct Materials

View full text Add to dashboard Cite

Herein, multifunctional mimics of viral architectures and infections self‐assembled from tailor‐made dendritic lipopeptides for programmed targeted drug delivery are reported. These viral mimics not only have virus‐like components and nanostructures, but also possess virus‐like infections to solid tumor and tumor cells. Encouragingly, the viral mimics provide the following distinguished features for tumor‐specific systemic delivery: i) stealthy surface to resist protein interactions and prolong circulation time in blood, ii) well‐defined nanostructure for passive targeting to solid tumor site, iii) charge‐tunable shielding for tumor extracellular pH targeting, iv) receptor‐mediated targeting to enhance tumor‐specific uptake, and v) supramolecular lysine‐rich architectures mimicking viral subcellular targeting for efficient endosomal escape and nuclear delivery. This bioinspired design make in vivo tumor suppression by drug‐loaded viral mimics against BALB/c mice bearing 4T1 tumor greatly exceed the positive control group (more than three times). More importantly, viral mimics hold great potentials to reduce side effects and decrease tumor metastasis after systemic administration.

show abstract

Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor

Cited by 199 publications

References 134 publications

Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy

Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy

A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery

Virus‐Inspired Mimics Based on Dendritic Lipopeptides for Efficient Tumor‐Specific Infection and Systemic Drug Delivery

Contact Info

Product

Resources

About